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2 
INTRODUCTION 
 
 Cancer, modern epidemics of non-communicable diseases is 
the second commonest cause of mortality in developed countries 
and remains one of the ten commonest causes of mortality in 
developing countries like India is a complex disease with altered 
expression, abnormal growth and disruption of normal function of 
cells caused by genotoxic effects resulting genomic instability at an 
early stage of cancer. 
 To evaluate the genotoxic risks/ effects, observed as DNA 
damages, can be assessed by chromosomal aberrations, sister 
chromatid exchanges and micronucleus test. Out of all these, 
micronucleus test is found to be the most sensitive when 
compared with other tests as it neither requires tedious procedures 
like cell culture and metaphase preparation, nor it requires any 
specific DNA stains. To further add, as it is applicable on 
interphase cell only , it is the best indicator of mitotic interference 
and chromosomal mutations or breakages and is noninvasive and 
economical too. 
                                                  1 
2 
 
 Micronucleus, a microscopically visible round or oval 
cytoplasmic chromatin mass in the extra nuclear vicinity, originates 
from aberrant mitosis. It consists of eccentric chromosomes, 
chromatid fragments or whole chromosomes which failed to reach 
spindle poles during mitosis. Micronuclei have been used as 
biomarkers for assessment of DNA damages. Micronuclei provide 
a measure of both, chromosome breakage and chromosome loss. 
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2AIMS AND OBJECTIVES 
 
  
1. To identify the occurrence of micronuclei in normal and 
cancer cervix. 
2. To identify the occurrence of micronuclei in risk factors of 
cancer cervix. 
3. To identify the occurrence of micronuclei in different stages 
of malignancy. 
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2REVIEW OF LITERATURE 
Carcinoma cervix worldwide accounts for 15% of all cancer 
diagnosed in women [1]. It is the second most common cancer in 
women globally and 80% of these occur in developing countries. It 
occupies either top rank or second among cancers in developing 
countries, whereas, in the affluent countries does not find place 
even in the top five leading cancers.  
In India it has been reported to be the commonest 
malignancy in women, comprising 24% of all cancers in female[2]. 
Almost 20 per 100,000 Indian women have cancer cervix and it 
has been estimated that one in 63 likely to suffer from it in her life 
time [3,4]. It is estimated that approximately 100,000 women 
develop cancer cervix every year. [5] 
The Indian Council of Medical Research initiated a network 
of cancer registries under the National Cancer Registry Program 
(NCRP) in 1981 and data collection commenced in these registries 
from January 1982 [6]. Cancer incidence is generally expressed as 
Age Adjusted or Age Standardized Incidence Rates (AAR) per 
100,000 persons according to world standard population. Among 
females, the most common sites of cancers are breast and cervix. 
 
2 Cancer of the cervix has been the most important cancer in 
women in India over the past two decades. In older population 
based cancer registries (PBCR) Barshi and Chennai PBCRs have 
always recorded the highest incidence of cervix cancer [7]. Based 
on the data of the PBCRs, the estimated number of new cancers 
during 2007 in India was 90, 7086. 
 Cancer of the cervix accounted for 16 per cent of all cancers 
in women in the urban registries in 2005. Since over 70 per cent of 
the Indian population resides in the rural areas, cancer cervix still 
constitutes the number one cancer in either sex [6]. 
 In all developing countries as in India, maternal morbidity 
and mortality are points of cynosure. However besides direct 
gynaecologic and obstetric complications, another important issue 
leading to these outcomes is the high incidence of cervix cancer 
especially among the economically – disadvantaged [15] 
In fact the total incidence of mortality from cancer at all sites 
is greater in the lower socio-economic groups and is due mainly to 
increased incidence and mortality at certain sites including the 
cervix uteri [8].  
2Risk for cervical cancer has been reported to be variable 
from one population group to another because of its multifactorial 
etiology [9].  
It appears that a larger proportion of the Indian female 
population is more vulnerable to cervical neoplasia, since the 
recognised risk factors for cancer cervix like illiteracy, low socio-
economic status, early menarche, early marriage, multiparity, first 
child birth at an early age, poor genital hygiene and genital 
infections are widely prevalent in this population [3, 4].  
Increasing age, increasing parity (Para > 3) age at marriage, 
clinical lesions of the cervix, gynecological complaints, STD were 
the risk factors  for SIL and cancer cervix. 67.8% of the total SIL 
and 85.4% of the carcinoma cervix was observed in women with 
high parity ( 3 or more children ). 51.5% of the total SIL and 75.3% 
of the total cancer cases were observed in women more than 40 
years of age [6] 
The highest age specific incidence rate for cancer was seen 
in more than 60 years of age. Cancer cervix patients were in the 
age group  of 28 to 75 years and they had mostly married young in 
the age of 15 years [5]. 
2The frequency of cancer cervix showed a progressive risk 
with increasing parity mostly between Para 2 and 3. [10] 
The relative risk of cervical cancer increases with the more 
number of abortions [11]. 
There is a correlation between the low SES and cancer 
cervix. It has in fact been observed that uneducated women due to 
lack of knowledge of proper hygiene and preventive measures are 
more prone to cancer cervix [8]. 
However, cancer of the cervix responds favorably to 
secondary prevention measures as it has a long pre-clinical phase 
that usually requires 2 to 10 years to penetrate the basement 
membrane and invade tissues [12]. 
Statistics reveal that about 4 cases of every 5 cervical 
carcinoma patients actually occur in those countries that are 
without screening programs [13].  
In fact in developed countries, 80% of cases are curable 
because of early detection while in developing countries, 80% of 
cases are incurable at the time of detection if they are detected at 
all [14]. 
2 Rather, women do not come forward for routine 
gynaecological examination due to lack of knowledge about its 
early symptoms, fear of cancer (fatalistic attitude) and lack of 
awareness about the possibility of a cure [15]. 
In a WHO bulletin in 2001 there were the recommendations 
regarding Effective screening programs in the developing countries 
like India for cervical cancer in low and middle income groups [16] 
The choice of screening test in countries/ regions that plan to 
initiate new programs should be based on the comparative 
performance characteristics of cytology and its potential 
alternatives such as VIA (visual inspection with acetic acid) [17] 
Since programs cannot afford the luxury of frequently 
repeated testing of women, a highly sensitive test should be 
provided.  Owing to their limited resources, developing countries 
cannot afford the models of frequently repeated screening of 
women over wide age ranges that are used in developing 
countries [16]. 
 If cytology is chosen, considerable attention should be given 
to obtaining good Quality smears, staining, and reporting so that a 
moderately high sensitivity to detect lesions is ensured. If a 
2potential alternative to cytology, such as VIA, is chosen for 
screening, considerable attention should be given to the proper 
monitoring and evaluation of the program inputs and outcomes 
before further expansion[16]. 
 A single life time screening which appears to most 
affordable and feasible method of control of cancer cervix in 
developing countries like India should be carried out in all women 
of high parity ( 3 or more children) irrespective of age and in all 
women above the age of forty irrespective of parity was the 
conclusion of the study[18].            
Regular screening can be achieved by imparting appropriate 
education to the masses regarding the early signs and symptoms 
of cervix cancer and utilizing rapid screening/ diagnostic 
measures. 
 Routine protocol empathizes that every female above 25 
years should annually get a Pap smear examination as a 
screening procedure [15]. 
Marked reductions in morbidity and mortality from cervix 
cancer have been achieved among screened persons [15]. 
2Mass screening by cytology, to detect precursors of cancer 
of uterine cervix, is among the most successful of health 
measures. Survival of cervix cancer patients is most directly 
related to the stage of disease at diagnosis, and the best way to 
increase detection of cervical neoplasm in pre-cancerous or 
localized stage is to improve the scope and quality of cytology 
screening [16]. 
Pap smear is the most frequently used test in mass 
screening programs introduced by George Papanicolaou in 1940, 
yet it is not totally reliable. [42] 
The sensitivity of Pap smear for the detection for cervical 
cancer precursors is less than 50%. The rate of false negativity is 
about 20 to 30 % in women with high grade CIN and 10 to 15 % in 
women with invasive cancer [43] 
Long term exposure to genotoxic factors leading to mutations 
has been proved to be related to the increasing incidence of 
carcinoma due to toxicity resulting in genomic instability being 
found in its early stages of carcinoma [21, 22].  
2The occurrence of genetic instability, either as a result of, or 
leading to, an increase in chromosomal rearrangements in most 
cancer types merits cytogenetic investigations. 
The genomic instabilities have been observed in many forms 
like chromosomal instability[23], chromosomal breakage[21], 
nucleoplasmic bridges[23], micronucleus formation and double 
DNA strand breaks[22].Chromosomal instability usually results 
either from abnormal centriole formation or chromosomal loss in 
anaphase or mal-segregation of chromosome or mitotic slippage 
or failure of cytokinesis or nucleoplasmic bridges[23], whereas 
chromosomal breaks are caused by spindle apparatus and 
clastogenic mutations[21]. 
Among all these genomic instabilities seen to carcinomas, 
MN formation is the hallmark of genomic instability being defined 
as chromatin containing body that represents fragments or even 
whole chromosomes which failed to get incorporated into the 
daughter cell nucleus during mitosis or might result from DNA 
strand breakage[22]. 
The clastogenic effects can be also used as an effective 
screening measure for detection of cervical cancer in its pre-
2clinical stage, in combination with morphological, biochemical and 
cytogenetic parameters, the Comet Assay along with the 
Micronucleus Test (MNT) may serve as novel tools to detect and 
predict the stage of cervical dysplasia [24]. 
Micronuclei can be detected in exfoliated cells of the buccal 
mucosa, urinary bladder, cervix or bronchi and seem to reflect 
chromatid and chromosome aberrations which occurred in the 
proliferating basal layers [23, 24, 25].  
The sampling of such exfoliated cells is generally fast and 
highly economical; the MN assay has been the method of choice 
for survey of large population groups especially as a preliminary 
indicator for pre-cancerous lesions [23].  
Since more than a century ago, micronuclei have been 
described by many scientists. In the late 1800s and early 1900s 
Howell and Jolly described Feulgen-positive nuclear bodies in 
human reticulocytes, known as Howell–Jolly bodies, and 
representing chromosomes separated from the mitotic spindle[26]. 
In the early 1970s the term Micronucleus test (MN Test) was 
suggested for the first time by Boller and Schmidt and Heddle who 
showed that this assay provided a simple method to detect the 
2genotoxic potential of mutagens after in vivo exposure of animals 
using bone marrow erythrocytes [26]. 
 Many methods like chromosomal aberration analysis, sister 
chromatid exchange analysis and MN frequency have been 
indentified for detecting mutagen exposures [21]. Out of these MN 
assay has been found to be an important genotoxic screening test 
for the detection of agents which cause chromosomal damage and 
induced the formation of MN in interphase cells [22]. 
Chromosomal biomarkers of genomic instability related to 
carcinoma have been identified as MN formation, nuclear budding 
and non disjunction in the year 2002 by Fenech. As per his 
observations, the DNA damage rates in human population can 
best be measured by MN scoring rather than chromosomal 
aberrations [23]. The MN frequency was used in number of studies 
and was found to be of significant importance [27]. 
MN index has also been labeled as endogenous dosimeter in 
tissues that might be the future site for the development of 
carcinoma [28]. 
As observed, more than 90% of human cancers were 
epithelial in origin and exposure of dividing cells to mutagens 
2resulted either in chromosomal breakage or in MN formation, so 
MN assay can be used to assess the genetic damage in such 
tissues [29] 
The cells from the basal layer of epithelium continuously 
divide differentiate and migrate to the upper cell layers. The MN 
frequency was observed from these exfoliated epithelial cells. 
Induction of MN, in processes associated with DNA damages like 
cancer, aging and other genetic disorders, has been considered as 
an effective biomarker [30]. 
Since more than 90% of the human cancers arise from the 
epithelial tissue, exfoliated cells hold a strong potential as a tool for 
biomonitoring human populations exposed to genotoxic agents. 
Various studies indicate the presence of MN in the exfoliated cells 
of buccal mucosa, nasal mucosa, urothelium, lymphocytes and 
erythrocytes[21].But, of all these tissues and cells, exfoliated cells 
have been considered as best surrogate for predicting cancer and 
they can be easily collected from the mouth, nose,and bladder by 
noninvasive procedures[30]. 
The micronucleus test is used as a biomarker for chromo-
some instability and malignancy, observing higher frequencies of 
2micronucleated cells among cancer patients than among healthy 
individuals [31]. 
A gradual increase in MN frequency has been observed from 
normal to precancerous to cancerous lesions [32]. 
 Many genotoxic studies on MN frequency were conducted 
related to predisposing factors which conclude significantly higher 
MN frequency in people with risk factors [33]. 
Number of micronuclei correlates with the severity of genetic 
damage. Cells containing several micronuclei present greater 
genetic damage than do cells that present only one micronucleus 
[34]. 
Human Micronucleus Project (HUMN) is an international 
collaborative study on the use of micronucleus technique for 
measuring DNA damage in humans. It validated the MN assays in 
human cells [30].  
Epithelial tissues are in immediate contact with inhaled and 
ingested genotoxic agents, and kidney and bladder cells are also 
in contact with metabolites of the chemicals. Genotoxic changes in 
bronchial, esophageal, cervical, breast duct and other types of 
epithelia have also been reported [30]. 
2 An important component in the interpretation of MN assay 
results is cell kinetics. MN observed in exfoliated buccal, nasal or 
urothelial epithelia are not induced when the cells are at the 
epithelial surface, but when they are in the basal layer [39]. 
In general, cells take 7–16 days to emerge to the surface 
and exfoliate [30]. 
Variability of MN assessment arises from intraindividual 
variability, interindividual variability, and population variability, as 
well as variations characteristic of different cell types. When 
spontaneous MN frequencies were compared in different healthy 
individuals, up to a 17-fold difference was observed, possibly 
reflecting genetic and nonspecific exposure differences. 
HUMN[30]. 
The average reported healthy population MN frequency is  
1–3 per 500 - 1000 cells, with no significant variation between 
different types of exfoliated cells. Repeated scoring of MN in 
epithelia from the same individuals showed variation between 30 
and 102.9%.HUMN[40].      
 Increases in the MN frequency in exfoliated cells were also 
observed as a result of exposure to pesticides or neoplastic drugs 
2radiotherapy, smoking, arsenic in drinking water w56x, and chronic 
infection. Exposures to low levels of benzene or leather tanning 
solutions did not cause significant increases in cytogenetic 
damage[30].                                                                                                           
A causal association between MN frequency and cancer risk 
could be inferred from studies of structural chromosomal 
aberrations(CAb) and aneuploidy. Somatic chromosome damage 
is involved in cancer etiology. Such damage can occur via 
chromosome loss as well as by breakageThere is a direct 
association between the frequency of MN in target or surrogate 
tissues and cancer development [30]. 
Michael Fenech have given  detailed description of the 
scoring criteria for the micronucleus assay (MN ASSAY) in the 
HUMN project [41]. 
1. Morphologically identical but smaller than nuclei  
2.  Round or oval in shape 
3.  Diameter between 1/3rd and 1/16th of main nuclei  
4.  Nonrefractile  
5.  Not linked to main nucleus   
26. May touch but not overlap the main nucleus and the 
micronuclear boundary should be distinguishable from the 
nuclear boundary. 
7. Same color as nucleus  
8. Similar staining intensity or more as nucleus 
There are three mechanisms that may contribute towards the 
formation of micronuclei: metabolic stress caused by tumor growth, 
clastogenic products released from tumor cells and the presence 
of HPV. 
Micronuclei is detected in the the exfoliated cells of the 
buccal mucosa, urinary baldder, cervix or bronchi and seem to 
reflect chromarid and chromosome aberrations which occurs in the 
proliferating basal layers[25]. 
The sampling of the exfoliated cells is fast and economical, 
the MN assay  has been the method of choice for survey of large 
populations especially as a preliminary indicator for precancerous 
lesions[30].  
2The presence of micronuclei has been considered to be a 
very useful biomarker for detecting malignant cervical uterine 
carcinomas[35].  
A  significant MN count was observed in  the presence of risk 
factors like illiteracy, low SES, early marriage and more number of 
conceptions[15]. 
A significant MN assay was observed in patients who were 
between 21 to 30 years and 51 to 60 years of age[36]. 
The maximum number of MN was seen in the age group 
between 40 to 60 years of age[34]. 
The frequency of MN cells increases with advancing age and 
that observed in 51 to 60 years age group are 3 folds higher than 
in age group of 21 to 30 years[36]. 
When the MN count in patients less than 17 years of age  
was compared to that of patients more than 18 years, non 
significant result was observed[37]. 
For the factor age at marriage significant MN count was seen 
in patients less than 17 years of age[36] 
2The trend for percent frequencies of MN cells at different 
parity levels exhibits non significant difference at low parity level 
but statistical difference at the higher parity levels[36,37]. 
There is a significant difference in MN count in the lower 
SES and middle SES group[36]. 
There is a strong association between MN frequency and 
staging of cancer cervix and there is a linear association both MN 
frequency and stage of the cancer cervix. The highest frequency of 
MN observed in stage III B[37].  
There is an association between lesion severity and 
micronucleus frequency in epithelial cells, which contributes 
towards validating micronucleus frequency as a possible 
biomarker for cancer risk[38]. 
Significant MN count was observed even without abnormal 
PAP smear. This is because the sensitivity of MN assay in 
detecting the genomic instability at an early stage in the 
carcinogenesis[37]. 
The sensitivity and specificity  for MN assay in urine cytology 
was72 % and 83.3% respectively. The efficiency was found to be 
77.55%. This test has got a good negative predictive value[15]. 
2Percent frequencies of micronucleated  cells were highest in 
the patients with stage III, older patients, younger age at 
marriages, increased parity and low socioeconomic status[36]. 
The test in urothelial cells indicates damage in the tissue 
which is not site of cancer cervix. They also observed that elevated 
micronucleus frequencies parallel with the cytogenetic 
damage[36]. 
The frequency of MN in lymphocytes (0.18), buccal smears 
(2.40) and urothelial cells ( 0.5 to 1)  in control groups is generally 
reported to be low[15]. 
Damage in urothelial cells was increased despite the lesser 
number of scorable cells and damage in cervix smears was also 
significantly more than in controls yet it was generally lesser than 
in urothelial cells except when analysed for the age variable. This 
is quite surprising since urothelial cells do not constitute cells of 
the cervix but comprise cells from the renal tubular, squamous and 
bladder epithelia[36]. 
The percent frequency of MN ranged from 0.101 to 0.756 
while the cells scored varied from 0 to 9 in the patient population.  
The over all frequency of MN cells (0.324 ± 0.024) in the patients’ 
2group was statistically significant (0.031 ± 0.023) from that 
observed in control (MN present in 24% of subjects) individuals. In 
the control group individuals, the highest frequency of MN 
observed was 0.220[15].                                                                                        
The frequency of MN cells in the buccal smears  
lymphocytes and urothelial cells has been observed to be low in 
the controls.Specifically when MN assay were made in the 
urothelial cells in the healthy controls it was observed to be 
low[36]. 
Percentage of MN among 10 cancer patients was 1.36%, in 
controls it was 0.35% only[15]. 
There was significant increase in the number of MN in 
cancer patients prior to the initiation of chemotherapy and 
radiotherapy when compared with healthy subjects[38]. 
MN can be used as a biomarker and as an important assay 
to find out the cancer in early stages. MN in exfoliated cells reflect 
genotoxic events that occurred in the dividing basal layer 1-3 
weeks earlier. An assay in exfoliated cells holds promise as a site 
specific biomarker of exposure to genotoxins for cancer risk. 
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2MATERIALS AND METHODS 
The present descriptive study was undertaken in the patients 
attending the gynecology out patient department with complaints of 
leucorrhea, post-coital bleeding, lower abdominal pain, inter 
menstrual bleeding and prolongation of menstrual bleeding. 
Patients were grouped in the following 2 categories: 
1. Patients whose Visual Inspection of Cervix is normal were 
taken as Group A. 
2. Patients whose Visual Inspection of Cervix shows positive 
findings were taken as Group B. 
A Standard Performa was prepared in order to record the 
history, general examination and pelvic examination. 
After making the proper recordings in the respective 
Performa, urine sample were collected from the patients.  
After collection of the urine sample, the slides were prepared 
following the protocol given by Chakrabarti and Dutta et al (1988) 
for the MN assay. 
2Materials required: 
1. Slides (microscopic). 
2. Sterile plastic containers. 
3. Cover slips. 
4. Methanol. 
5. Giemsa stain. 
6. May-Grunwald’s stain 
7. Methanol  
8. Phosphate buffer 
9. Distilled water 
PROCEDURE: 
 Collection of Specimens:  
1. Patients   
2. Local clinical examination were done by using Cuscos self 
retaining vaginal  speculum and the different lesions were 
noted. 
¾ Erosion cervix – a bright red area surrounding and 
extending beyond the external os on the ectocervix 
with a clearly demarcated outer edge. 
¾ Hypertrophied cervix – the size of the cervix is 
enlarged. 
2¾ Suspicious and unhealthy cervix- if abnormal 
growth, ulcer or vasculature is seen. 
3. Erosion and unhealthy cervix – cervical biopsy done and 
staged later if malignancy documented. 
4. Obvious growth cervix was staged by clinical examination 
(FIGO staging system). 
5. Patient was requested to collect mid stream urine sample 
(~ 10 ml) in sterile plastic containers. And were 
transported to the laboratory. They were processed within 
3-4 hrs of sample collection. The procedure, briefly, 
entailed sample wash thrice in phosphate buffered saline 
(PBS) with alternate centrifugations at 1200 rpm for 10 
minutes. From the pellet, smear preparations were made 
on pre-cleaned glass slides. Up to 2-3 slides per case 
were made and these were allowed to air dry. After air 
drying, the slides were kept absolute methanol for 20 
minutes for fixation of cells. 
  
 
2Preparation of stains: 
1. May-Grunwald’s stock solution: 
‐ 25 mg of May-Grunwald powder was mixed with 100 
ml of methanol  
‐ It was mixed properly with help of a mixer 
‐ It was filtered properly and stored in dark coloured  
air tight bottle.  
2. Giemsa stock solution : 
‐ Giemsa powder 1 gm was dissolved in 60 ml of 
glycerin and kept in water bath at 60 * Celsius for 2 
hrs. 
‐ Mixture was cooled to room temperature and 66 ml 
of absolute methanol was added, thus made 
solution was filtered and stored in dark airtight 
bottle. 
Preparation of working solution 
1. Giemsa working solution was prepared in the proportion 
of 3 parts of stock solution and 1 part of distilled water. 
22. May –Grunwald working solution  was prepared in the 
proportion of 2 parts of stock solution and 1 part of 
distilled water. 
Procedure of staining: 
‐ The slides were kept in May-Grunwald stain for 5 
minutes. 
‐ The slides were rinsed twice with distilled water. 
‐ After washing , it was counter stained with Giemsa 
satin for  
8 to 10 minutes, followed by washing with distilled 
water. 
‐ Stained slides were mounted with cover slip  
‐ They were observed for nuclear abnormalities under 
bright field binocular microscope under low power 
(40 x). 
‐ The presence of Micronucleus was confirmed under 
oil immersion (100 x). 
‐ Observations were recorded and tabulated. 
2Method of Analysis: 
  Five Hundred cells were recorded in each patient from the 
slides prepared and the incidence of micronucleus were recorded 
and the collected data was subjected to Student’s Independent‘t’ 
test. 
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OBSERVATIONS 
 
 
 
 
 
 
 
 
 
2OBSERVATIONS 
The present study was conducted from April 2009- May 
2010. A total number of 60 patients who had undergone clinical 
examination for gynaecological complaints in the gynecological out 
patient dept at the Institute of obstetrics and Gynecology, Egmore 
were included in our study. 
Observations were recorded on the personal history and 
clinical examination findings and the MN assay. The observed data 
was tabulated for analysis. 
Out of the 60 cases, 23 cases had no findings on Visual 
inspection of cervix (GROUP A), 29 cases had growth cervix on 
examination and 8 cases had erosion cervix on examination. Both 
were taken as (GROUP B). TABLE 1  
Out of the 60 cases, 23 cases in GROUP A were in the age 
group from 18 to 65 yrs and 37 in GROUP B were in the age group 
21 to 72 yrs.  TABLE 1 
 
 
2According to the patients age the patients were divided into 4 
groups. 
< 30 yrs group1,30–39yrs grp2,40– 49yrs grp3 and > 50 yrs 
grp 4.TABLE 9 
The mean age in GROUP A was 36.5yrs and in GROUP B 
was 44yrs. TABLE 2 
A statistically significant difference was observed between 
the two groups in terms of age. TABLE 3 
 Among the 60 cases 4 were commercial sex workers. The 
rest 56 cases, 12 GROUP A cases and 12 GROUP B cases got 
married before the age of 18 yrs.TABLE 4 
 Among the 56 cases, 26 GROUP B cases and 13 GROUP A 
cases had history of abortions (> 1) and in 10 GROUP B cases 
and 7 GROUP A cases there was no history of abortions.  17 
cases had 1 abortion, 13 had 2 abortions and 9 had more than 3 
abortions. TABLE 5 
 Among the 36 cases in GROUP B, 17 had more than 3 
childbirths and 17 had 2 childbirths. Among the GROUP A, 6 had 
more than 3 childbirths and 14 had 2 childbirths TABLE 6  
2 Among the 60 cases 17 were in the lower socioeconomic 
status and 26 were in the upper lower SES. Only 17 were in the 
middle SES.TABLE 7 
 Among the 37 cases in GROUP B  , distribution of the cancer 
cervix cases were  1 in stage IA , 4 STAGE IB , 8 in STAGE IIA ,6 
in STAGE IIB, 5 in STAGE III A & 6 in STAGE IIIB. TABLE 8 
 37% of the GROUP B cases who had significant MN counts 
were more than 50 yrs of age. But significant MN counts were 
seen in cases < 30 yrs   and 40 to 49 yrs in GROUP A . This 
difference was statistically significant. TABLE 9 
 60% of GROUP A cases got married before the age of 17 
and they had significant MN count. The rest 40 % of GROUP A 
cases got married after 18yrs had significant MN count. But in 
GROUP B cases significant MN count was equally distributed in 
both groups (50 % distributed equally). The difference was not 
statistically significant. TABLE 10 .Chi square test 0.660 
50% of GROUP A  with significant MN counts had 2 
abortions and 55.6% of GROUP B  with significant MN counts had  
1 or 2 abortions. 35% of GROUP A cases and 27% of GROUP B 
cases with no history of abortions had significant  MN counts. 15% 
2of GROUP A cases and 16% of GROUP B cases with 3 abortions 
had significant MN counts. But it was not statistically significant. 
TABLE 11 
 70% of GROUP A cases and 53% of GROUP B cases with 
less than 2 child birth   had significant MN counts. 30% of both 
GROUP A and GROUP B cases who had 3 childbirth had 
significant MN counts. No cases in GROUP A with more than 3 
children had significant MN count. 16% in GROUP B with more 
than 3 children had significant MN count. TABLE 12 
 22% of GROUP A cases and 32% of GROUP B cases in the 
lower SES had significant MN counts. 45% in GROUP A and 43% 
in GROUP B, in the upper lower SES had significant MN counts. 
32% in GROUP A and 24% in GROUP B, in the middle SES had 
significant MN counts. TABLE 13. But the MN count in the upper 
SES was not statistically significant. 
Among the GROUP B cases, 21.6% with cancer cervix stage 
IIA, 18.9% with cancer cervix stage III B had significant MN counts. 
Among the GROUP A cases significant MN counts were seen in 
18.6%.The difference was proven to be statistically significant. 
TABLE 14 
2There is a linear association between mean MN count and 
stage of the cancer cervix. TABLE 15 
 The sensitivity of the MN test in GROUP A was 83.8 % and 
specificity was 82.6 % .The Efficiency of the test was found to be 
83.3 %.  TABLE 16 
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2 
TABLES AND FIGURES 
DISTRIBUTION OF CASES IN GROUP A  & GROUP B 
TABLE 1 
 
VALID 
FREQUENCY 
PERCENT 
1 23 38.4 
2 29 48.3 
3 8 13.3 
TOTAL 60 100 
 
 
GROUP A –   1 (  VISUAL INSPECTION OF CERVIX – NORMAL)  
GROUP B –   2 AND 3 ( VISUAL INSPECTION OF CERVIX – ABNORMAL ) 
                                       (   2 = GROWTH CERVIX   ,  3 = EROSION CERVIX  ) 
 
MEAN AGE IN GROUP A & GROUP B. 
TABLE 2 
Group N Mean Std.deviation Median Minimum Maximum
A 23 36.59 12.912 39.00 18 65 
B 37 44.84 11.934 43.00 18 72 
TOTAL 60 41.76 12.843 40.00 18 72 
 
 
 
2T TEST 
Table 3 
 
T test for equality of means 
t df Sig  (2-tailed) 
Age Equal variances assumed 
Equal variances not assumed 
-2.490 
-2.440 
57 
41.5 
.016 
.019 
Age is statistically significant 
 
Distribution of cases according to Age at marriage 
TABLE 4 
Age in years Frequency  Percent 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
CSW 
1 
2 
4 
10 
9 
4 
12 
8 
1 
1 
2 
0 
1 
1 
4 
1.7 
3.4 
6.8 
16.9 
15.3 
6.8 
20.3 
13.6 
1.7 
1.7 
3.4 
0 
1.7 
1.7 
6.8 
TOTAL 60 100 
 
2 
Distribution  of cases  according to the Number of Abortions 
Table 5 
 
Number  of 
Abortions 
FREQUENCY PERCENT 
0 
1 
2 
3 
4 
CSW 
17 
17 
13 
6 
3 
4 
28.8 
28.8 
20.4 
9.1 
5.1 
6.8 
TOTAL 60 100 
 
Distribution of cases according to Parity 
Table6 
Number of Parity Frequency              Percent  
1 
2 
3 
4 
5 
CSW 
3 
30 
17 
5 
1 
4 
5.1 
50.8 
28.1 
7.5 
1.7 
6.8 
TOTAL 60 100 
 
2 
Distribution of cases according to Socioeconomic status* 
Table 7 
 
Socioeconomic status*  FREQUENCY PERCENT 
1 
2 
3 
4 
17 
26 
13 
4 
28.3 
43.3 
21.6 
6.8 
TOTAL 60 100 
 
** modified kuppuswamy scale. 
1= LOWER SES , 2 = UPPER LOWER SES , 3 = LOWER 
MIDDLE SES , 4 =UPPER MIDDLE SES.  
 
Distribution of cases according to Cancer cervix Stage. 
Table 8 
 
Stage FREQUENCY PERCENT 
I A 
I B 
II A 
II B 
III A 
III B 
1 
4 
8 
6 
5 
6 
3.4 
13.6 
27.2 
20.4 
17.0 
20.4 
TOTAL 30 100 
 
2 
 
Frequency of MN count in different Age groups 
Table 9 
 
Group  Age ( yrs ) 
MN count 
0 – 3  4 & more 
A  < 30  44.4%  25% 
  30‐ 39  11.1%  0 
  40‐ 49  38.9%  50% 
  > 50  5.6%  25% 
B  < 30  16.7%  9.7% 
  30‐ 39  50%  22.6% 
  40‐ 49  33.3%  29% 
  > 50  0  38.7% 
 
 
 
2Frequency  of MN count according to Age at marriage** 
Table 10 
 
Group Age at marriage (yrs) MN count 
0 -3 4 & more 
A Less than 17 
More than 17 
64.7% 
35.3% 
33.3% 
66.7% 
B Less than 17 
More than 17 
50% 
50% 
50% 
50% 
 
** 4 commercial sex workers were not included in the analysis 
Frequency  of MN count according to Number of Abortions 
Table 11 
 
Group No. of Abortions 
MN count 
0-3 4 & more 
A Nil 
1 – 2 
3 & more 
41.2% 
52.9% 
5.9% 
0 
33.3% 
66.7% 
B Nil 
1 – 2 
3 & more 
66.7% 
33.3% 
0 
20% 
60% 
20% 
2 
Chi-Square Tests 
Group Value df 
Asymp. Sig. 
(2-sided) 
A Pearson Chi-Square 7.712a 2 .021 
Likelihood Ratio 6.588 2 .037 
Linear-by-Linear Association* 5.475 1 .019* 
N of Valid Cases 20   
B Pearson Chi-Square 5.760b 2 .056 
Likelihood Ratio 5.977 2 .050 
Linear-by-Linear Association* 5.000 1 .025* 
N of Valid Cases 36   
 
*THERE IS  A LINEAR ASSOCIATION BETWEEN THE MN COUNT AND 
NUMBER OF ABORTIONS. 
 
 
 
 
 
 
 
 
 
 
2 
Frequency of  MN count according to Parity. 
Table 12 
Group Parity 
MN count 
0-3 4 & more 
A 
Less than 2 
3 
4 & more 
76.5% 
23.5% 
0 
33.3% 
66.7% 
0 
B Less than 2 
3  
4 & more 
83.3% 
16.7% 
0 
46.7% 
60% 
20% 
frequency of MN count  according to SES**. 
TABLE 13. 
 
Group 
SES 
MN count 
0-3 4 & more 
A 
1 
2 
3 
16.7% 
50% 
33.3% 
50% 
25% 
25% 
B 
1 
2 
3 
33.3% 
50% 
16.7% 
32.3% 
41.9% 
25.8% 
 
**Modified Kuppusamy scale.SES : 1 = LOWER , 2 = UPPER LOWER , 3 = 
LOWER & UPPER  MIDDLE 
MN CELLS : 1 = 0 to 3 cells , 2 = 4 & more cells. 
2 
Frequency  of MN count in Cancer cervix stage. 
Table 14 
 
CANCER CERVIX STAGE MN frequency 
I A 2.9% 
I B 11.4% 
II A 22.9% 
II B 17.1% 
III A 14.3% 
III B 17.1% 
 
 
Chi square test 
 
 Value df Asymp.Sig(2 sided) 
Pearson Chi Square 41.980 7 .000 
Likelihood ratio 53.452 7 .000 
No. valid cases 60
 
Statistically significant  
 
 
2 
 
Data for MN assay in Urothelial cells in Group A & Group B 
TABLE 16 
 
MN assay in 
Urothelial cells 
Test Results 
(no. of individuals) 
Total 
Group A       Group B 
MN present 4 31 35 
MN absent 19 6 25 
Total 23 37 60 
 
SENSITIVITY - 31/ 37= 83.8% 
SPECIFICITY – 19 / 23 = 82.6 % 
EFFICIENCY =  50 / 60 =0.833= 83.3% 
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DIAGRAMS AND CHARTS 
 
 Data for MN assay in Urothelial cells in  
Group A & Group B 
 
0
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2 
Cancer cervix stage and Mean MN count. 
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Sensitivity = 83.8% 
Specificity = 82.6 %  Efficiency = 83.3 % 
Diagram showing Sensitivity , Specificity & Efficiency of MN count in Group A cases. 
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2 
DISCUSSION 
 
Complexity of the cancer could be attributed to its altered 
expression, abnormal growth, invasion of tumor and disruption of 
normal functioning which probably results from genomic instability. 
The present study was undertaken to identify the feasible 
and economical method which could be used as a screening test 
in the population for identifying the effects of genomic instability. 
Cancer of the cervix has been the most important cancer in 
women in India over the past two decades. Cancer of the cervix 
accounted for 16 per cent of all cancers in women in the urban 
registries in 2005. However, it constitutes 37 per cent of the 
cancers in females in Barshi. The highest age specific incidence 
rate of 98.2 per 100,000 for cancer cervix was seen in the 60-64 yr 
age group. Since over 70 per cent of the Indian population resides 
in the rural areas, cancer cervix still constitutes the number one 
cancer in either sex. 
According to Nandakumar et al and Misra et al the highest 
age specific incidence rate for cancer was seen in more than 60 
years of age. Most of the GROUP B cases in our study was above 
50 years. 
2According to Gandhi et al cancer cervix patients were in the 
age group of 28 to 75 years and they had mostly married young in 
the age of 15 years. In our study GROUP B cases were in the age 
group of 21 to 72 years and most of them got married by 18 years. 
So our findings are well correlated with Gandhi et al , Nandakumar 
et al and Misra et al. 
According to Murthy  et al the frequency of cancer cervix 
showed a progressive risk with increasing parity mostly between 
Para 2 and 3. But our findings contradict with the findings of 
Murthy et al and in our study the frequency of cancer cervix is 
more  in Para 1 and 2. According to Castenada et al the relative 
risk of cervical cancer increases with the more number of 
abortions. This is similar to the results shown by Gandhi et al 
where one of the patients with advanced stage cancer cervix had 
six spontaneous abortions. This is well correlated with our study. In 
our present study there is linear association between the number 
of abortions and stage of cancer cervix. 
According to Tomatis et al there is a correlation between the 
low SES and cancer cervix. It has in fact been observed that 
uneducated women due to lack of knowledge of proper hygiene 
and preventive measures are more prone to cancer cervix. This 
2analysis by Tomatis at al and Arora et al are in accordance with 
our findings. 
Data for the MN cells have been grouped with respect to 
stage of cancer, age of patients and some of the recognized risk 
factors in cancer cervix etiology like low SES , early marriage and 
multiparity according to Dutta et al. 
Present study confirms the findings reported by Gandhi et al 
in 2005 where he reports significant damage was observed in 
patients who were between 21 to 30 years and 51 to 60 years of 
age. In our study significant MN count was seen age group 
between 40 to 49 years and more than 50 years of age. But our 
findings fall in line with the observations made by Leal-Garza et al 
where the maximum number was seen in the age group between 
40 to 60 years of age. 
In the present study the frequency of MN cells observed in 
51 to 60 years age group are 3 folds higher than in age group of 
21 to 30 years. Our findings are in accordance with findings 
reported by Gandhi et al in 2002. In other intermittent age group 
there was trend in stepwise increase in MN frequency which was 
observed in our study too. 
2Among the GROUP A cases significant MN count was seen 
in 40 to 49 yrs age group, the reason being the presence of risk 
factors like illiteracy , low SES , early marriage and more number 
of conceptions. One patient in  GROUP A with significant MN 
count was a CSW, who’s PAP smear showed ASCUS. 
For the factor age at marriage significant MN count was seen 
in patients less than 17 years of age which is in concordance with 
the findings of Gandhi et al 2003. When the MN count in patients 
less than 17 years of age  was compared to that of patients more 
than 18 years, non significant result was obtained as in the study 
done by Gandhi et al in 2002. In the present study MN count was 
seen in patients married after 18 years in the GROUP A patients. 
According to Gandhi et al and Lawson et al the number of 
pregnancies is significant risk factor for cancer cervix. In the 
present study the number of conceptions in GROUP A and 
GROUP B was 20 and 36 respectively. This is in concordance with 
the observations of Fonn et al in his study. 
Kurl et al reported multiparity as a recognized risk factor in 
cancer cervix. In the present study 46.7% showed less than 2 
children and 53.3% more than 3 children which was not statistically 
2significant. Our findings did not compare well with the findings of 
Kurl et al. Jain et al also reported similar findings. 
In a study by Capalesh et al, he observed that low SES 
status which has a correlation with poor genital hygiene is a 
significant risk factor for inducing cancer cervix, which is in 
accordance with the present study where 73.2% of the cases were 
in the lower SES. Gandhi et al reported significant difference in MN 
count in the lower SES and middle SES group. Present study 
showed in GROUP A, 75% were in the low SES group and 25% in 
the middle SES group. In GROUP B 73% were in the low SES 
group and 27% were in the middle SES group. 
According to Chakrabarthy et al, there is a strong association 
between MN frequency and staging of cancer cervix. In our study 
there is a linear association both MN frequency and stage of the 
cancer cervix. Mean values of MN was 5 in stage I A, 7  in stage I 
B, 8.5 in stage  II A , 11.8 in stage II B , 15 in stage III A , 17 in 
stage III B. This linear Association was statistically significant.  
The highest frequency of MN observed in stage III B.  
(0.18 %). She belongs to a low SES and her age at detection was 
64 years though her age at marriage was 18 years. Her 
reproductive history showed 8 conceptions and 4 abortions. 
2Significant MN count was seen  in 4  cases of GROUP A 
who had normal PAP smear. This is because the sensitivity of MN 
assay in detecting the genomic instability at an early stage in the 
carcinogenesis. This has been analysed in the study made by  
Gandhi et al. 
When assessing the mean MN frequency in the GROUP A 
which was 0.0525% which is in accordance with the study made 
by Gandhi et al in 2003. 
The sensitivity and specificity was calculated for MN assay in 
urine cytology in the present study in GROUP A. Sensitivity was 
83.8% and Specificity was 82.6 %. The Efficiency was found to be 
83.3 %. These values showed that MN test in Urothelial cells has 
got good negative predictive value. This confirms the findings 
given by Gandhi et al in 2005 where the sensitivity was 72 %, 
specificity was 83 %  and the efficiency was 77.5%. 
The emergent views from this study indicate that the MN 
assay in urothelial cells , after validation, may prove beneficial to 
perform in screening programmes of cervix cancer given the  
non-invasive method of sample collection, easier availability of 
urine and the rapidity of the assay. 
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SUMMARY AND CONCLUSION 
 
2SUMMARY  
 
 
1. Maximum numbers with abnormal findings on Visual 
Inspection of Cervix [GROUP B] were in the age group of 
more than 50 years. 
2. 20% of the cases in GROUP B got married before 18 
years of age. 
3. 72% of the cases in GROUP B had the history of more 
than 2 abortions. 
4. 47% in GROUP B had more than three childbirth. 
5. 72.9% of the cases were in the low socioeconomic status 
group. 
6. 50 % of the GROUP cases who were in age group of 40 
to 49 yrs and 38.7 % of the GROUP B cases who were 
more than 50 yrs had significant MN count was more than 
50 years of age. 
7. A statistically significant MN count was seen in the 
different stages of cancer cervix. 
28. A linear association was noted between the mean MN 
count and cancer cervix stage.  
9. 18.2% of the GROUP A cases had significant MN count. 
10. 33.3 % of GROUP (normal findings in Visual Inspection of 
Cervix) cases who had significant MN count got married 
before 17 years of age. 
11. 6.6% of the total cases were CSWs (commercial sex 
workers) among them one had erosion cervix and ASCUS 
on PAP smear. Two of them had significant MN count. 
12. Sensitivity and Specificity of MN count in GROUP A was 
83.8% and 82.6 % respectively. The Efficiency was 83.3 
%. 
 
 
 
 
 
 
 
 
2CONCLUSION 
 
1. Early marriage, recurrent abortions, multiparity are 
associated with Cytologic changes in cancer cervix. 
2. There are cases who had normal findings on Visual 
Inspection of Cervix but with significant MN count concludes 
that they are more prone for malignant transformation, needs 
further follow up. 
3.  MN assay is an easy, non invasive, cost effective method 
and hence to be used as a screening test for a large 
population. 
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RECOMMENDATIONS 
 
2RECOMMENDATIONS 
 
1. Sample size can be taken at a higher scale  
2.  More number of cells (> 10000) with quantification of 
DNA damage can be done by automated MN assay and it 
can be used as screening test. 
3. MN assay can also be done in cervical smear cytology. 
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ANNEXURES 
2ANNEXURE – I 
 
Points for identification of MN: 
1. Morphologically identical but smaller than nuclei  
2. Round or oval in shape 
3. Diameter between 1/3rd and 1/16th of main nuclei  
4. Nonrefractile  
5. Not linked to main nucleus   
6. May touch but not overlap the main nucleus and the 
micronuclear boundary should be distinguishable from the 
nuclear boundary. 
7. Same color as nucleus  
8. Similar staining intensity or more as nucleus 
 
 
 
 
 
 
 
 
2ANNEXURE – II 
PROFORMA 
Name 
Age 
 
Religion
Occupation 
Address
Phone no‐ 
Op no: 
 
Urine sample no: 
 
Complaints 
Duration  
Menarche 
Menopause 
Postmenopausal 
bleeding 
Menstrual history
 
LMP 
 
Marital history 
 
Obstetric history
 
 
No of children 
 
Alive
Last childbirth 
 
 
No of abortions 
Past history  
 
Contraception 
  Other systems
Examination  of 
Abdomen 
 
 
Visual  inspection  of 
cervix 
Diagnosis
Results
 
 
2Observation  
 
Slide no:  Op no:   Urine  
sample no: 
Visual 
inspection 
of cervix  
Diagnosis Results 
No of 
cells 
MN   MN 
frequency 
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